










































Fifty years ago, Leonhard Hayflick discovered that the 
number of cell divisions is limited for cells in culture 
[1] - after about 40 to 60 divisions the proliferation rate 
decays until the cells ultimately enter a senescent state. 
This phenomenon applies to all somatic cells in culture 
which are not immortalized.  
 
It is often anticipated, that replicative senescence is 
caused by accumulation of cellular  defects.  Progressive  
 
 










































shortening of telomeres or modified telomeric structures 
have been demonstrated to be an important trigger for 
replicative senescence [2]. It is however still 
controversially discussed if telomere shortening is really 
the initiating mechanism for replicative senescence or if 
it is rather a consequence of this process [3,4]. 
Alternatively, it has been suggested that replicative 
senescence is induced by oxidative stress, UV light or γ-
irradiation [5,6]. This has led to the perception, that 
long-term culture leads to the accumulation of 




































Abstract:  Cells  in  culture  undergo  replicative  senescence.  In  this  study,  we  analyzed  functional,  genetic  and  epigenetic
sequels of long‐term culture in human mesenchymal stem cells (MSC). Already within early passages the fibroblastoid colony‐
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emerging field of regenerative medicine [7].  
 
Mesenchymal stem cells (MSC) comprise a 
subpopulation of multipotent adult stem cells that is 
able to differentiate into diverse mesodermal cell 
lineages [8]. Despite intensive research over the last 
decade there are still no reliable markers for this 
multipotent subset and therefore MSC are alternatively 
termed “mesenchymal stromal cells” [9]. The ease of 
culture expansion to large cell numbers has fuelled the 
hope for regenerative medicine. MSC are concurrently 
tested in a large number of clinical trials for a wide range 
of therapeutic applications (www.clinicaltrials.gov). So 
far, no critical side effects have been reported [10]. 
However, oncogenic transformation and transplant 
related tumor formation are like a “sword of 
Damokles” for cellular therapy [11]. Human MSC 
appear to be more resistant to in vitro transformation 
than murine MSC, with little genomic instability and 
no tumor-induction after transplantation [12-14]. 
Reports indicating malignant transformation of human 
MSC have recently been withdrawn as they were 
caused by cross-contamination with established 
immortalized cell lines [15,16]. However, MSC 
preparations may reveal transient aneuploidy without 
transformation [17] and highly proliferative culture 
conditions such as addition of human platelet lysate 
(HPL) might increase genomic instability upon culture 
expansion [18,19].  
 
Long-term culture has also been suggested to induce 
epigenetic modifications [20-22]. CpG dinucleotides in 
the genomic DNA can be methylated at cytosine 
moieties. We have recently analyzed age-associated 
DNA methylation changes in MSC from human bone 
marrow [23] and dermal fibroblasts [24] using the 
HumanMethylation27 BeadChip microarray. This 
platform allows determination of DNA methylation 
levels at 27,578 unique CpG sites within more than 
14,000 promoter regions. Overall, methylation patterns 
of MSC were maintained throughout both long-term 
culture and aging whereas highly significant 
modifications occur at specific CpG sites.  
 
In continuation of this work we have now analyzed the 
molecular sequel of culture expansion of MSC from 
adipose tissue. We did not detect relevant chromosomal 
aberrations but there were significant differences in the 
DNA-methylation patterns of MSC derived from bone 
marrow and adipose tissue. Furthermore, senescence-
associated DNA-methylation changes were observed in 




Long-term culture of MSC  
 
Mesenchymal stem cells from adipose tissue were 
expanded in culture medium with human platelet lysate 
(HPL) until they entered replicative senescence. 
Overall, the proliferation rate remained relatively high 
during the first two months before it declined. No age or 
gender-associated correlations were observed in long-
term growth curves (figure 1A). All cell preparations 
entered growth arrest after 138 ±20 days and 53.8 ±14.4 
cumulative population doublings (CPD). However, 
CPD do not necessarily correspond to the mean number 
of cell divisions as proliferation is heterogeneous in 
MSC: only a subset gives rise to new colonies upon 
passaging. To address the percentage of these highly 
proliferative cells we have tracked the frequency of 
fibroblastoid colony forming units (CFU-f) over 
subsequent passages. It was striking that the frequency 
of highly proliferative CFU-f declined continuously 
from about 20% in the first passage to less than 1% 
after two months (figure 1B). To accommodate the fact 
that the progeny of each passage is based on a 
decreasing number of highly proliferative cells, we have 
alternatively calculated the number of population 
doublings for each passage divided by the corresponding 
CFU-f frequency. This method of CFU-f-adjusted growth 
curves results in much higher numbers of cumulative 
population doublings (CPD
CFU-f; figure 1C).  
 
Senescent MSC displayed the typical large and flat 
cellular morphology. They also expressed senescence-
associated (SA) beta galactosidase, which is a 
biomarker for cellular senescence and can be quantified 
with the fluorogenic substrate C12FDG. Neither 
morphological changes nor increase of SA-β-gal 
activity were observed during the exponential growth 
phase between passage 5 and passage 10 (figure 2A,B). 
The typical immunophenotypic pattern of MSC was 










+; figure 2C). Another parameter for the 
definition of MSC is their in vitro differentiation 
potential [9]. Quantitative analysis of osteogenic and 
adipogenic differentiation revealed, that the 
differentiation potential decays already within early 
passages. Similar results have been described by many 
other groups before [25-28] (figure 2D,E). 
 
Analysis of genetic aberrations 
 
Genomic stability is an important concern for clinical 
use of MSC [7,17]. Therefore, we have compared the 
karyotypes of four MSC preparations at early passage 
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passage 32 of donor 12 as these cells entered the 
senescent state later than the other cell preparations 
(figure 2F; table 1; in total 167 mitoses were analyzed). 
All MSC revealed a normal 2n karyotype with no 
consistent chromosomal aberrations. Only 3 mitoses in 
two samples of early passage showed additional 
chromosomes and these might represent artifacts.  
 
To detect smaller chromosomal lesions we used single 
nucleotide polymorphism (SNP) arrays (table 2). This 
method does not account for the heterogeneity within 
cells in culture, but it can detect small chromosomal 









































individual subclones. Some regions showed gains and 
losses at 200 kb resolution - most of them were 
consistent between early and later passage and may 
therefore be donor specific. Few aberrations were 
detected only in either early or late passage and these 
copy number variations were restricted to small 
genomic regions. These few gains and losses are most 
likely due to technical noise or to differences in the 
reference DNA pool. Taken together, MSC from 
adipose tissue are relatively resistant to genomic 
instabilities even under highly proliferative growth 
conditions with HPL. This corresponds to our results for 
MSC from bone marrow [14] and those of many other 

























































DNA methylation profiling 
 
Subsequently, we analyzed if MSC acquire epigenetic 
modifications upon expansion. DNA methylation 
profiles of early passage (P5) and later passage (P10) of 
the four samples were compared using the Human-
Methylation27 BeadChip microarray. We have 
















































methylation changes in MSC from bone marrow which 
were either isolated from bone marrow aspirates (MSC-
BM) or from the caput femoris upon hip fracture of 
elderly donors (MSC-Hip) [23]. Raw beta-values of 
adipose tissue and bone marrow derived datasets were 
quantile normalized together for subsequent analysis of 
epigenetic differences. Unsupervised principal 
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the first dimension indicating that there are marked 
differences in their epigenetic make up. The second axis 
separated the samples predominantly according to 
gender (supplemental figure 1). Notably, the forth 
component (PC4) separated the DNA-methylation 
profiles of MSC in those of early and later passages 
(figure 3A) and this demonstrates that expansion of 
MSC has a very consistent impact on DNA-methylation 
profiles.  
 
To further elaborate epigenetic differences between 
MSC from different tissues we have only considered 
data of early passages for a direct comparison of MSC-
AT  versus MSC-BM and MSC-Hip. Scatter plot 
analysis revealed that 1021 CpG sites were more than 
15% hyper-methylated whereas 1175 CpG sites were 






































mental figure 2). Alternatively we have used the 
Bayesian method Significance Analysis of Microarray 
(SAM) to estimate the false discovery rate (FDR): 8,370 
of the 27,578 CpG sites represented on the microarray 
were differentially methylated (FDR = 5%). We have 
focused on the 539 most significantly differentially 
methylated CpG sites (FDR < 0,0001%) for functional 
categorization of genes which correspond to these 
genomic sites. Genes with tissue-specific DNA-
methylation changes were most significantly enriched in 
the Gene Ontology categories for nutrient level, lipid 
modification and glucose metabolism (supplemental 
figure 3A). This may reflect the different function of 
these tissues. The results demonstrate that MSC from 
different tissues have considerable different DNA-
methylation profiles although their growth pattern, 
immunophenotype and in vitro differentiation potential 








































sample passage  days  in  culture 
(no. of CPD) 
no. of mitoses 
(no. of slides) 
karyotype abnormalities 
donor 4  5  25d (22.7)  20 (15)  46,XX  1 x 47,XX,+C 
1x 47,XX,+mar 
 10  46d  (34.8)  16  (7)  46,XX  - 
donor 8  5  21d (18.8)  11 (4)  46,XX  1x 47,XX,+19 
  10  40d (32.8)  22 (10)  46,XX  - 
donor 10  3  14d (14.2)  11 (4)  46,XY  - 
 10  44d  (30.0)  22  (10)  46,XY  - 
donor 11  5  25d (22.9)  14 (6)  46,XX  - 
  10  46d (36.2)  14 (6)  46,XX  - 
donor 12  8  36d (28.6)  15 (6)  46,XY  - 






















































































































aspirated  from  the  iliac  crest  (MSC‐BM)  or  taken  from  the  caput  femuris  upon  hip  replacement  (MSC‐Hip).
Unsupervised  principal  component  analysis  (PCA)  clearly  separated  DNA‐methylation  profiles  according  to  the
tissue of origin in the first dimension (PC1), whereas the forth component (PC4) discerned early and late passage
(A). Scatterplot comparison of passage 5 and passage 10 in MSC‐AT revealed that 233 CpG sites are more than 15%

































Subsequently, we have focused on long term culture-
associated changes in MSC-AT. Overall the DNA-
methylation level remained relatively constant in 
comparison of passage 5 and passage 10, whereas 233 
CpG sites became more than 15% hyper-methylated and 
186 CpG sites were hypo-methylated upon replicative 
senescence (figure 3B). For further analysis, we have 
focused on those CpG sites with the most significant 
senescence-associated changes in all MSC preparations. 
517 CpG sites were consistently differentially 
methylated in early versus late passages in MSC-AT, 
MSC-BM and MSC-Hip (pair wise SAM; FDR = 4.8%; 
156 CpG sites hyper-methylated and 361 CpG sites 
hypo-methylated upon replicative senescence; figure 
3C). Genes associated with CpGs that were significantly 
differentially methylated upon replicative senescence 
included distal-less homeobox 5 (DLX5), cyclin-
dependent kinase inhibitor 2B (CDKN2B) and 
homeobox D10 (HOXD10). Gene Ontology analysis 
revealed that senescence-associated DNA-methylation 
changes were significantly enriched in genes for 
defense response and epidermal development 
(supplemental figure 3B). This accumulation of 
epigenetic modifications in developmental genes 
supports the notion that replicative senescence is a 






























Senescence-associated DNA-methylation changes 
correlate with repressive histone marks 
 
The DNA-methylation pattern has been shown to be 
linked to histone modifications - especially methylation 
of histone H3 [31-33]. Therefore, we have compared 
our DNA-methylation profiles of MSC-AT, MSC-BM 
and MSC-Hip with previously published data on 
trimethylated H3K4 (H3K4me3) and H3K27me3 in 
human embryonic stem cells (hESC) [34], H3K4me3, 
H3K9me3 and H3K27me3 in human MSC-AT [35] and 
targets of the Enhancer of Zeste Homolog 2 (EZH2) in 
human MSC-BM [36]. Initially, we have compared the 
overall methylation level in all 27,578 CpG sites on the 
microarray with the methylation levels of those CpG 
sites which have been assigned for histone 
modifications. The median methylation level of all CpG 
sites was 5.4%. Those CpG sites that have previously 
been associated with the H3K4me3 mark in hESC and 
MSC-AT showed a significantly lower methylation 
level (2.9% and 4.1% respectively). In contrast, CpG 
sites which carried only H3K27me3 (13.6% and 49.2%) 
or H3K9me3 (45.8%) were associated with much higher 
levels of methylation. EZH2 mediates H3K27 
trimethylation and accordingly, EZH2 targets were also 
linked to significantly higher DNA-methylation levels 
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notion, that DNA-methylation is associated with 





















































Subsequently, we have analyzed if the 517 senescence-
associated DNA-methylation changes are enriched in 
regions with these specific histone modifications. 
Statistical analysis with hypergeometric distribution 
revealed that they are significantly enriched with 
H3K27me3 (P = 1.2 * 10
-9), H3K9m3 (P < 10
-20) and 
EZH2 target regions (P = 5.8 * 10
-4) (figure 4B). This is 
in line with the fact that the senescence-associated CpG 
sites displayed a much higher median methylation level 
(47.2%) compared to all CpG sites on the microarray. 
Thus, senescence-associated DNA-methylation changes 
are associated with repressive histone marks and with 
targets of the polycomb protein EZH2. These results 
indicate that epigenetic histone modifications contribute 
to senescence-associated changes in the DNA-




Human MSC are relatively stable towards chromosomal 
aberrations whereas long-term culture induces highly 
reproducible epigenetic modifications at specific sites in 
the genome. These epigenetic modifications may 
govern senescence-associated functional changes such 
as loss of differentiation potential upon several 
passages. Therefore, culture expansion and passaging 
clearly have to be taken into account for cellular 
therapy.  
 
Replicative senescence does not occur synchronously in 
cell preparations. We have demonstrated that the 
percentage of colony initiating cells declines already 
within the first passages. This indicates that many cells 
have a restricted proliferative capacity in the 
exponential growth phase but these are quickly 
outgrown by more proliferative subpopulations. 
Therefore typical morphological changes or senescence-
associated  β-galactosidase are hardly observed until 
these proliferative subpopulations reach senescence, 
too. So far, calculation of cumulative population 
doublings is based on the ratio of cells seeded and cells 
harvested at each passage - this however does not 
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which consequently undergo more cell divisions than 
expected. On the other hand our CFU-f adopted 
growth curves are solely based on highly proliferative 
cells and the real average number of cell divisions lies 
between the conventional and CFU-f adopted long-
term growth curves. This exemplifies that it is not an 
easy task to track replicative senescence of MSC in 
vitro [11]. 
 
Apart from this continuous loss of proliferative 
subpopulations, it is of central importance if specific 
clones confer selective growth advantage or promote 
cell transformation [17]. Addition of 10% human 
platelet lysate results in very fast proliferation of MSC-
AT and this may further trigger accumulation of 
genomic aberrations [18]. Our cell preparations 
revealed a normal karyotype although abnormalities 
were observed in few individual cells and SNP-arrays 
did hardly detect gains or losses of certain 
subpopulations. Since all MSC preparations reached a 
senescent state upon long-term culture and stopped 
proliferation, the detected genetic alterations did not 
promote cell transformation but rather confer to growth 
disadvantages due to DNA damage. These observations 
are in line with several other studies, which indicated 
that human MSC are relatively resistant to genomic 
aberrations and transformation in culture expansion [12-
14,17,30]. Despite absence of major clinical side effects 
a potential risk remains that transplantation of MSC 
may harbor some tumorigenic potential – especially in 
autologous transplant settings. On the other hand, it is 
highly questionable if karyotypic analysis or SNP-
arrays can safeguard this issue [17]. 
 
MSC are characterized by plastic adherent growth, a 
panel of immunophenotypic surface markers and their 
ability to differentiate towards osteogenic, adipogenic 
and chondrogenic lineage [9]. All our MSC 
preparations passed these criteria, but this relative 
superficial definition of MSC does not account for the 
differences which arise from different methods for cell 
preparations [39]. We and other authors have 
demonstrated, that MSC from adipose tissue and bone 
marrow have different gene expression profiles [40-
42]. Here, we have shown that the DNA-methylation 
profile differs also markedly between MSC from 
adipose tissue and bone marrow. For fibroblasts, it has 
even been shown that DNA methylation profiles of 
cells from the same dermal region clustered closely 
together indicating that fibroblasts maintain positional 
memory despite in vitro culture [24]. Hence, the tissue 
of origin appears to be imprinted in cell preparations 
and this might relate to functional differences between 
MSC preparations. 
In this study, we have demonstrated that specific 
changes in the DNA-methylation pattern arise already 
during the exponential phase of culture expansion 
(between passage 5 and passage 10). Many of these 
senescence-associated changes were related to those 
between early and senescent passage in MSC from bone 
marrow [23]. This highly consistent modification at 
specific CpG sites – many of which are associated with 
developmental genes – indicates that replicative 
senescence represents a developmental process, rather 
than a random accumulation of cellular defects.  
 
Long-term repression in the course of replicative 
senescence requires the ability to maintain localized 
silencing through many cell divisions. Therefore, DNA-
methylation provides an ideal mechanism as the 
methylation pattern is established on the newly 
synthesized DNA strand by DNA methyltransferase 1 
(DNMT1) [43,44]. On the other hand, it has been shown 
that DNA-methylation patterns are better correlated 
with histone methylation patterns than with the 
underlying genome sequence context [31,32,37,38]: 
DNA-methylation is associated with absence of 
H3K4me3 and presence of H3K9me3. This association 
was also clearly observed by combination of our DNA-
methylation data and previous published ChIP-seq and 
ChIP-chip datasets in MSC-AT and MSC-BM. More 
importantly, senescence-associated DNA-methylation 
changes were highly significantly enriched in regions 
with H3K9me3, H3K27me3 and EZH2 targets. In 
contrast, H3K4me3 has been suggested to disrupt the 
contacts between nucleosomes making DNA sequences 
accessible for zinc finger proteins which protect CpG 
islands from DNA methylation [38]. The histone 
methyltransferase EZH2, a component of the polycomb-
repressive complex 2 (PRC2) has previously been 
implicated in replicative senescence [45,46,46,47]: 
EZH2 levels are down-regulated in senescent cells [48]. 
Targeting of EZH2 with short hairpin interference 
results in senescence whereas over-expression bypasses 
senescence [49]. On the other hand, EZH2 
overexpression is associated with a variety of cancers 
and inhibition of polycomb group proteins has been 
suggested as a potential therapeutic strategy [50-52]. 
Components of PRC1 are also capable of delaying the 
onset of senescence in fibroblasts [48,53] and the 
precise composition of senescence-regulating 
complexes is yet unknown. Furthermore, regulatory 
mechanisms gain another dimension of complexity by 
various microRNAs that have been implicated in 
regulation of replicative senescence [27,54-56]. 
 
If replicative senescence represents an epigenetically 
regulated developmental program then the question 
remains how this confers a selective advantage. It might 
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of cellular defects which might ultimately result in cell 
transformation and tumor formation [57]. Since the 
discovery of the “Hayflick limit” it has also been 
speculated if it is related to the aging process of the 
organism [58-61]. We have previously demonstrated a 
moderate but significant concordance in molecular 
changes upon long-term culture in vitro and aging in 
vivo – this was observed on gene expression level [62] 
and DNA-methylation level [23,24]. It has been shown 
that polycomb group protein targets (PCGT) are far 
more likely to become methylated with age [63]. We 
did not observe a significant association of senescence-
associated DNA-methylation changes with the 69 age-
associated CpG sites described in this study (results not 
shown) but we have demonstrated that they are 
associated with targets of EZH2 which represents a 
component of the PCR2. Other authors have shown that 
age-associated hyper-methylation occurs predominantly 
at bivalent chromatin domain promoters in CD4
+ T-cells 
and CD14
+ monocytes [64]. Our study demonstrates 
that senescence-associated DNA-methylation changes 
in MSC are rather associated with repressive histone 
marks than with bivalent modifications (H3K4me3 and 
H3K27me3). Epigenetic modifications upon replicative 
senescence in vitro and aging in vivo seem to be related 
but it might be expected that the complex regulatory 
mechanisms differ in these two processes [7,65]. 
 
In summary, expansion of MSC is associated with a 
systematic modulation of the epigenetic chromatin 
structure at specific sites in the genome but the precise 
regulation of this process is yet unknown. We have 
demonstrated that senescence-associated hyper-
methylation and hypo-methylation were often observed 
in regions with H3K9me3, H3K27me3 and targets of 
EZH2. Therefore it is conceivable, that replicative 
senescence is regulated by protein complexes such as 
PRC2. Notably, replicative senescence appears to be 
reversible: induced pluripotent stem cells as well as 
ESC and germline cells do not show signs of replicative 
senescence in long-term culture [66]. Furthermore, 
replicative senescence can be pharmacologically 
decelerated: cells retain their proliferative capacity 
during cell cycle arrest in the presence of rapamycin, an 
inhibitor of mTOR [67,68]. Selective manipulation of 
this process might ultimately facilitate expansion of 




Isolation of MSC. MSC from adipose tissue (MSC-AT) 
were isolated from lipoaspirates at RWTH Aachen 
University after written consent of all participants. 
These studies were performed according to the 
guidelines of the Ethics Committee of the RWTH 
Aachen University Medical School, Germany (Permit 
number 163/07) that specifically approved this study. 
Lipoaspirates were washed in 9 g/L NaCl, digested with 
2 g/L collagenase type I (PAA, Pasching, Austria) and 
passed through a 100 µm cell strainer as described 
before [19]. Culture medium consisted of Dulbecco´s 
Modified Eagles Medium-Low Glucose (DMEM-LG; 
PAA) with 2  mM L-glutamine (Sigma Aldrich, St. 
Louis, MO, USA), 100  U/mL penicillin/streptomycin 
(pen/strep; Lonza, Basel, Switzerland) and 10% human 
platelet lysate (HPL) which was pooled from five 
platelet units of healthy donors as described before [69]. 
Cells were cultured at 37°C in a humidified atmosphere 
containing 5% carbon dioxide with medium changes 
twice per week. Freshly isolated cells were seeded in 
parallel in limiting dilutions in two 96-well plates (100, 
300, 1,000 and 3,000 cells per well; 48 replica for each 
condition) to determine the initial fibroblastoid colony-
forming unit (CFU-f) frequency. 
 
Long-term culture of MSC.  MSC were always 
harvested by trypsinisation upon 80% confluent growth, 
counted with a Neubauer counting chamber (Brand, 
Wertheim, Germany) and additionally with a CASY cell 
counter (Schärfe System, Reutlingen, Germany) and re-
seeded in a density of 10,000 cells/cm
2 in culture flasks 
(Nunc Thermo Fisher Scientific, Langenselbold, 
Germany). Cell Population doublings per passage 
(PDP) and cumulative population doublings (CPD) 
were calculated from the first passage onward by the 
following formula [19]: PDPi = log2 (hi  /si); CPD = 
sumi=1...n PDPi, where n is the total number of passages; 
si is the number of cells seeded at passage i and hi is the 
number of cells harvested in passage i. In parallel, cells 
were seeded in limiting dilutions in 96-well plates (1, 3, 
10 and 30 cells per well; 48 replica for each condition) 
to calculate the CFU-f frequency over subsequent 
passages. After 14 days all wells were scored for more 
than 50% confluent growth. Based on these results, we 
alternatively calculated CFU-f corrected doublings per 
passage: PDP






Senescence associated β-galactosidase staining. 
Expression of pH dependent senescence associated β-
galactosidase (SA-β-gal) activity was analyzed with a 
fluorescence-based method for quantitative and 
sensitive analysis by flow-cytometry as described 
before [70]. In brief, Bafilomycin A1 (Sigma, St Louis, 
MO, USA) prevents lysosomal acidification and 
subsequently 5-dodecanoylaminofluorescein di-β-D-
galactopyranoside (C12FDG, Invitrogen, Eugene, OR, 
USA) was used as fluorogenic substrate for β-
galactosidase. 
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was analyzed on a FACS canto II (Becton Dickinson 
[BD] , San Jose, USA) upon staining with the following 
antibodies as described before [19]: CD14-
allophycocyanin (APC, clone M5E2, BD), CD29-
phycoerythrin (PE, clone MAR4, BD), CD31-PE (clone 
WM59, BD), CD34-APC (clone 8G12, BD), CD45-
APC (clone HI30, BD), CD73-PE (clone AD2, BD), 
CD90-APC (clone 5E10, BD), CD105-fluorescein 
isothiocyanate (FITC, clone MEM-226 Immuno Tools). 
  
In vitro differentiation.  Osteogenic, adipogenic and 
chondrogenic differentiation of MSC were 
simultaneously performed as described before [8,27]. 
After three weeks, osteogenic differentiation was 
analyzed by Alizarin Red staining and quantified with a 
Tecan infinite M200 plate-reader (405 nm) [71]. 
Adipogenic differentiation was analyzed by staining of 
fat droplets with the green fluorescent dye BODIPY 
(4,4-difluoro-1,2,5,7,8-pentamethyl-4-bora-3a,4a-diaza-
s-indacene) counter-stained with DAPI (4′,6-Diamidin-
2-phenylindol; both Molecular Probes, Eugene, Oregon, 
USA). Fluorescence microscopic pictures were always 
taken from five randomly chosen areas and the 
percentage of cells with fat droplets was determined as 
described before [19,69]. Images were captured at room 
temperature using a Leica DM IL LED microscope 
(Leica, Wetzlar, Germany) with a 10x dry objective 
(numerical aperture: 0.3; Leica) and a camera (Leica 
DFC420C) equipped with Leica application suite 3.3.1 
software (Leica). 
 
Cytogenetic analysis. To investigate structural and 
numerical chromosomal alterations we have performed 
conventional karyotyping of cultured MSC using GTG 
banding at 300 to 400 band level. Metaphase spreads 
were prepared using standard procedures of hypotonic 
treatment and methanol/acetic acid fixation (3:1). GTG 
-banding comprising a trypsin pretreatment was carried 
out according to standard protocols. Microscopy was 
performed with Axioplan fluorescence microscope 
(Carl Zeiss, Jena, Germany) and IKARUS
TM and 
ISIS
TM digital imaging systems (MetaSystems, 
Altlussheim, Germany). 11 to 22 GTG banded 
metaphases were analyzed for each sample. 
 
SNP array analysis. Copy number changes of DNA 
fragments were analyzed with the Affymetrix Genome-
Wide human single nucleotide polymorphism (SNP) 
array 6.0 which contains more than 1.8 million genetic 
markers. Genomic DNA was isolated from 10
6 cells 
using the DNA Blood Midi-Kit (Qiagen, Hilden, 
Germany). DNA quality was assessed with a NanoDrop 
ND-1000 spectrometer (NanoDrop Technologies, 
Wilmigton, Del) and agarose gel electrophoresis. For a 
reference, we have used a DNA pool of leucocytes of 
100 donors. 250 ng of genomic DNA were amplified, 
labelled and hybridized to the SNP Array according to 
the manufacturer’s instructions (Affymetrix Inc., Santa 
Clara, CA, USA). The arrays were stained and washed 
using a fluidics Station 450 and scanned with a 
GeneChip Scanner 3000 7G (both Affymetrix). 
GeneChip® Operating Software (GCOS), Genotyping 
Console v3.0.1 and Chromosome Analysis Suite 
(ChAS) software (all Affymetrix) were used for data 
analysis. Copy number variations were defined as gain 
or loss regions of at least 200 kb with a mean marker 
distance of not more than 5,000 base pairs. 
 
DNA-methylation profiling. DNA methylation profiles 
were analyzed using the HumanMethylation27 
BeadChip (Illumina, San Diego, USA) as described 
before [23]. In brief, about 200 ng of bisulfite converted 
DNA were applied per BeadChip according to the 
manufacturer’s instructions. After single-base extension 
using DNP- and Biotin-labeled ddNTPs, the array was 
fluorescently stained, scanned, and the intensities of 
non-methylated and methylated bead types measured. 
Initial data analysis was performed with the BeadStudio 
Methylation Module. DNA methylation values, 
described as beta values, are recorded for each locus in 
each sample and the complete dataset has been 
deposited in NCBIs Gene Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/geo/) and are accessible 
through GEO Series accession numbers GSE26519. 
 
Bioinformatic analysis of DNA methylation data. DNA-
methylation profiles of MSC-AT were analyzed in 
conjunction with the previously published data on MSC 
from bone marrow (GSE17448). The combined dataset 
was quantile normalized to minimize chip effects [72]. 
Principal  components analysis (PCA) was  calculated 
with prcomp in R package stats. Hierarchical clustering 
by Euclidian distance was performed using the 
MultiExperiment Viewer (MeV, TM4) [73]. Initially, 
we have selected CpG sites with differences in average 
beta value greater than 0.15 (more than 15% difference 
in mean methylation level) as this method is relatively 
resistant to potential confounding BeadChip effects. To 
select significantly differentially methylated CpG sites 
we used the Significance Analysis of Microarray 
(SAM) method [74] at a false discovery rate of less than 
5%. Genes associated with the differentially methylated 
CpG sites were classified by Gene Ontology analysis 
using    GoMiner   software   (http://discover.nci.nhi.gov/ 
gominer/).  
 
DNA-methylation profiles were subsequently compared 
with published chromatin immunprecipitation (ChIP) 
results: H3K4me3 and H3K27me3 were analyzed in 
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Illumina technology) [34], H3K4me3, H3K9me3 and 
H3K27me3 were analyzed in human MSC-AT 
(hybridized to NimbleGen RefSeq Promotor Array) [35] 
and EZH2 targets were analyzed in human MSC-BM 
(hybridized to NimbleGen RefSeq promoter array) [36]. 
For comparison, corresponding CpG sites on the 
HumanMethylation27 BeadChip were matched by 
RefSeq ID and subsequently by mapping to the 
chromosomal position (within 100 base pairs up- and 
down-stream of the target sequence). 
 
Statistics.  Quantification of in vitro differentiation 
assays is presented as mean ± standard deviation (SD). 
Probability of enrichment/depletion of senescence-
associated DNA-methylation changes was estimated by 
hypergeometric distribution. Representation of 
differentially methylated genes in Gene Ontology 
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Supplemental  Figure  1.  Principal  component
analysis  of  DNA‐methylation  profiles.  Principal 
component  1  (PC1)  separates  the  cell  preparations 




adipose  tissue  and  bone  marrow.  Scatterplot 
comparison of early passages of MSC‐AT versus those 
from MSC‐BM and MSC‐Hip (A). Heat map presentation 
of  DNA‐methylation  at  the  539  most  significantly
differentially  regulated  CpG  sites  between  MSC  from
adipose tissue and bone marrow (B; FDR = 0). 
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Supplemental Figure 3. Gene Ontology categorization of differentially methylated
genes. Genes associated with 539 differentially methylated CpG sites between MSC from
adipose tissue and bone marrow (A) or with 517 SA‐CpG sites (B) were categorized by Gene
Ontology and the most significantly over‐represented categories are depicted. 